Drug profile of ensidipine

Enasidenib is an oral small molecule drug that belongs to the class of IDH2 (isomeric cysteine synthase 2) inhibitors. It is designed to treat a specific type of leukemia, acute myeloid leukemia (AML), primarily in patients with AML who carry mutations in the IDH2 gene.

The mechanism of action of ensidipine involves inhibiting the abnormal enzyme activity caused byIDH2 gene mutations. IDH2gene mutation is one of the common abnormalities in some AML patients. It can lead to changes in the activity of isomeric cysteine u200bu200bsynthase 2 enzyme, thereby promoting the growth and proliferation of leukemia cells. By inhibiting this abnormal enzyme activity, ensidipine can block the growth and spread of leukemia cells, thereby achieving the purpose of treating AML.

Ensidipine is usually used as monotherapy, taken orally once daily. The dosage is generally 100mg (mg), and it is recommended to take it after meals to reduce the occurrence of digestive tract discomfort. The treatment cycle is usually 28 days, and patients need to continue taking ensidipine until the doctor determines the discontinuation time.

Although ensidipine has shown significant efficacy in treating patients with certain types ofAML, it may also cause some side effects. Common side effects include digestive system adverse reactions (such as nausea, vomiting, diarrhea), liver function abnormalities, bone marrow suppression, etc. Patients need to be regularly monitored and evaluated by doctors during treatment to ensure the effectiveness and safety of the treatment, and to deal with any adverse reactions in a timely manner.

In general, ensidipine, as a new type of AML therapeutic drug, represents the medical field's in-depth understanding of the leukemia treatment mechanism and provides a new treatment option for specific types of AML patients, providing new hope for improving patients' survival rate and quality of life.